Meloxicam SBEβCD Inclusion Complex for Migraine Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and delayed pain relief, which can be addressed by forming an inclusion complex with cyclodextrins like sulfobutyl ether β-cyclodextrin (SBEβCD) and administering it with a bicarbonate to enhance solubility and absorption.
Innovation Solution
The inclusion complex of meloxicam with SBEβCD and a bicarbonate, combined with rizatriptan, is orally or intravenously administered to patients with a history of inadequate response to prior migraine treatments, providing rapid and sustained pain relief by increasing bioavailability and absorption of meloxicam.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is administered alone, then the drug structure is simple, but the aqueous solubility is poor and bioavailability is reduced
Solution Approach 1:
Cyclodextrins serve as intermediary molecules that form inclusion complexes with meloxicam. The cyclodextrin cavity encapsulates the hydrophobic meloxicam molecule, while the hydrophilic exterior of the cyclodextrin interacts with aqueous environments, thereby solubilizing the drug and improving bioavailability without fundamentally altering the meloxicam structure
Solution Approach 2:
The formulation creates a composite system where meloxicam is combined with cyclodextrins and bicarbonates. This composite approach integrates multiple components with complementary properties: cyclodextrins provide solubility enhancement through inclusion complexation, while bicarbonates maintain gastric pH to prevent drug degradation and further enhance absorption
2Speed
If meloxicam is administered alone, then the formulation is simple, but the onset of pain relief is slow
Solution Approach 1:
Cyclodextrins act as carriers that facilitate rapid transport of meloxicam through biological membranes. The inclusion complex structure protects the drug during transit and enables faster absorption into the bloodstream, accelerating the onset of pain relief
Solution Approach 2:
The formulation changes the physical-chemical parameters of meloxicam by forming inclusion complexes. This transformation alters the drug's solubility, dissolution rate, and membrane permeability characteristics, enabling faster absorption and quicker onset of therapeutic effect
3Duration of action of moving object
If meloxicam is administered alone, then the treatment approach is simple, but pain relief duration is insufficient
Solution Approach 1:
The cyclodextrin inclusion complex provides continuous release of meloxicam as the complex dissociates in the gastrointestinal tract. This sustained release mechanism maintains therapeutic drug levels over an extended period, prolonging pain relief duration
Solution Approach 2:
The combination of cyclodextrins and bicarbonates creates a synergistic formulation that enhances both absorption and retention of meloxicam. The bicarbonate component maintains optimal pH conditions that prevent drug precipitation and ensure continuous availability, extending the duration of therapeutic action
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination significantly reduces the need for rescue medication and provides greater pain relief compared to meloxicam or rizatriptan alone, with improved bioavailability and faster onset of action, maintaining pain relief for extended periods.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
cyclodextrin compounds are also known to aggregate around a drug in a micelle-type structure
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.